Advanced search
Publication Cover
Current Medical Research and Opinion Volume 38, 2022 - Issue 3
Submit an article Journal homepage
1,708
Views
0
CrossRef citations to date
0
Altmetric
Oncology

Descriptive study on burden and communication of fatigue among castration-resistant prostate cancer patients in Japan

Taro Iguchia Department of Urology, Kanazawa Medical University, Ishikawa, JapanORCID Iconhttps://orcid.org/0000-0002-7067-6642
ORCID Icon,
Yusuke Nakamurab Market and Regional Access, Bayer Yakuhin, Ltd, Tokyo, JapanCorrespondence[email protected]
,
Takeshi Akiyamac Real World Evidence Solutions, IQVIA Solutions Japan K.K, Tokyo, Japan
,
Krishant Chandc Real World Evidence Solutions, IQVIA Solutions Japan K.K, Tokyo, Japan
&
Eric Yuc Real World Evidence Solutions, IQVIA Solutions Japan K.K, Tokyo, Japan
Pages 417-426 | Received 14 Apr 2021, Accepted 11 Nov 2021, Published online: 28 Dec 2021

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30.
  • Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): the ARCHES trial. 2019. American Society of Clinical Oncology.
  • Satoh T, Ledesma D, Yoshihara N. The economic burden of metastatic castration resistant prostate cancer and skeletal related events in japanese university hospitals. Asian Pac J Cancer Prev. 2018;19(1):21–26.
  • Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–1192.
  • Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512.
  • Vis AN, Schroder FH. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU Int. 2009;104(4):438–448.
  • Chung DY, Kang DH, Kim JW, et al. Comparison of oncologic outcomes between two alternative sequences with abiraterone acetate and enzalutamide in patients with metastatic Castration-Resistant prostate cancer: a systematic review and meta-analysis. Cancers (Basel). 2019;12(1):8.
  • Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019. Eur Urol. 2020;77(4):508–547.
  • Mohler JL, Antonarakis ES. NCCN guidelines updates: management of prostate cancer. J Natl Compr Canc Netw. 2019;17(5.5):583–586.
  • Vainio A, Auvinen A. Prevalence of symptoms among patients with advanced cancer: an international collaborative study. J Pain Symptom Manage. 1996;12(1):3–10.
  • Stone P, Hardy J, Broadley K, et al. Fatigue in advanced cancer: a prospective controlled cross-sectional study. Br J Cancer. 1999;79(9-10):1479–1486.
  • Degner LF, Sloan JA. Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. J Pain Symptom Manage. 1995;10(6):423–431.
  • Bower JE, Ganz PA, Desmond KA, et al. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol. 2000;18(4):743–743.
  • Hann DM, Jacobsen PB, Martin SC, et al. Fatigue in women treated with bone marrow transplantation for breast cancer: a comparison with women with no history of cancer. Support Care Cancer. 1997;5(1):44–52.
  • Smets EM, Visser MR, Willems-Groot AF, et al. Fatigue and radiotherapy: (A) experience in patients undergoing treatment. Br J Cancer. 1998;78(7):899–906.
  • Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory. Cancer. 1999;85(5):1186–1196.
  • Engl T, Drescher D, Bickeböller R, et al. Fatigue, depression, and quality of life in patients with prostatic diseases. Cent European J Urol. 2017;70(1):44–47.
  • Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects. BJU Int. 2013;111(4):543–548.
  • Rodriguez Antolin A, et al. Prevalence of fatigue and impact on quality of life in castration-resistant prostate cancer patients: the vital study. BMC Urol. 2019;19(1):92.
  • Holm M, Doveson S, Lindqvist O, et al. Quality of life in men with metastatic prostate cancer in their final years before death – a retrospective analysis of prospective data. BMC Palliat Care. 2018;17(1):126.
  • Restelli U, Ceresoli GL, Croce D, et al. Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study. Cancer Manag Res. 2017;9:789–800.
  • Drudge-Coates L, Oh WK, Tombal B, et al. Recognizing symptom burden in advanced prostate cancer: a global patient and caregiver survey. Clin Genitourin Cancer. 2018;16(2):e411–e419.
  • Srinivas S. Recent developments in the management of advanced prostate cancer. J Natl Compr Canc Netw. 2020;18(7.5):969–972.
  • Mock V. Fatigue management: evidence and guidelines for practice. Cancer. 2001;92(S6):1699–1707.
  • Burek CL, Talor MV. Environmental triggers of autoimmune thyroiditis. J Autoimmun. 2009;33(3-4):183–189.
  • Okuyama T, Wang XS, Akechi T, et al. Validation study of the Japanese version of the brief fatigue inventory. J Pain Symptom Manage. 2003;25(2):106–117.
  • Storey DJ, McLaren DB, Atkinson MA, et al. Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy. Ann Oncol. 2012;23(6):1542–1549.
  • Astellas. Xtandi tablets 40mg/80mg. Package insert. 2020;6.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.